Expression and clinical significance of S100A2 and p63 in esophageal carcinoma

Table 2 Relationship between the expression of S100A2 mRNA and S100A2 protein, and clinical pathological features in ESCC n (%)

	n	S100A2 mRNA		S100A2 protein
		Negative	Positive	Negative	Positive
Gender
Male	31	7	24 (77.4)	8	23 (74.2)
Female	9	2	7 (77.8)	3	6 (66.7)
Age (yr)
< 62	21	4	17 (81)	4	17 (81)
≥ 62	19	5	14 (73.7)	7	12 (63.2)
Clinical stage
I and II	31	5	26 (83.9)	6	25 (80.7)
III and IV	9	4	5 (55.6)	5	4 (44.4)
Tumor location
Upper and middle segment	23	3	20 (87)	5	18 (78.3)
Inferior segment	17	6	11 (64.7)	6	11 (64.7)
Tumor size (cm)
< 3.5	16	3	13 (81.3)	4	12 (75)
≥ 3.5	24	6	18 (75)	7	17 (70.8)
Depth of tumor invasion
Not to serosa	20	4	16 (80)	4	16 (80)
To serosa	20	5	15 (75)	7	13 (75)
Degree of differentiation
Well	15	1	14 (93.3)	2	13 (86.7)
Moderately	14	2	12 (85.7)	2	12 (85.7)
Poorly	11	6	5 (45.5)a	7	4 (36.4)b
Lymph node metastasis
Negative	25	2	23 (92)	2	23 (92)
Positive	15	7	8 (53.3)d	9	6 (40)d

^aP < 0.05,

^bP < 0.01 vs the well and moderately differentiated group;

^dP < 0.01 vs the lymph node-negative group.